Title: Full Text of HB3794
Official Title: 
Number of Sections: 1
Source: versions - Introduced
Media Type: text/html

================================================================================

Section 1:
Full Text of HB3794 ILGA.GOV HB3794 - 104th General Assembly 104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026HB3794 Introduced 2/18/2025, by Rep. Ryan Spain SYNOPSIS AS INTRODUCED: 5 ILCS 140/7.5215 ILCS 5/513b1225 ILCS 85/19.5    Amends the Pharmacy Benefit Manager Article of the Illinois Insurance Code. Provides that a covered individual's defined cost sharing for each prescription drug shall be calculated at the point of sale based on a price that is reduced by an amount equal to at least 80% of all rebates received, or to be received, or to be received, in connection with the dispensing or administration of the prescription drug. Provides that a health insurer or its agents shall not publish or otherwise reveal information regarding the actual amount of rebates a health insurer receives on a product or therapeutic class of products, manufacturer-specific basis, or pharmacy-specific basis and that the information is confidential. Defines terms. Amends the Freedom of Information Act to make a conforming change. Amends the Pharmacy Practice Act. Provides that a pharmacist may substitute a biological product (instead of an interchangeable biological product) if, among other requirements, the product being considered for substitution is either the reference product or a product approved by the United States Food and Drug Administration as a biosimilar of the prescribed biological product (instead of if the substituted product has been determined by the United States Food and Drug Administration to be interchangeable with the prescribed biological product). Makes conforming changes. LRB104 10437 BAB 20512 b  A BILL FOR HB3794LRB104 10437 BAB 20512 b1    AN ACT concerning prescription drugs. 2    Be it enacted by the People of the State of Illinois, 3represented in the General Assembly: 4    Section 5. The Freedom of Information Act is amended by 5changing Section 7.5 as follows: 6    (5 ILCS 140/7.5)7    Sec. 7.5. Statutory exemptions. To the extent provided for 8by the statutes referenced below, the following shall be 9exempt from inspection and copying:10        (a) All information determined to be confidential 11    under Section 4002 of the Technology Advancement and 12    Development Act.13        (b) Library circulation and order records identifying 14    library users with specific materials under the Library 15    Records Confidentiality Act.16        (c) Applications, related documents, and medical 17    records received by the Experimental Organ Transplantation 18    Procedures Board and any and all documents or other 19    records prepared by the Experimental Organ Transplantation 20    Procedures Board or its staff relating to applications it 21    has received.22        (d) Information and records held by the Department of 23    Public Health and its authorized representatives relating   HB3794- 2 -LRB104 10437 BAB 20512 b1    to known or suspected cases of sexually transmitted 2    infection or any information the disclosure of which is 3    restricted under the Illinois Sexually Transmitted 4    Infection Control Act.5        (e) Information the disclosure of which is exempted 6    under Section 30 of the Radon Industry Licensing Act.7        (f) Firm performance evaluations under Section 55 of 8    the Architectural, Engineering, and Land Surveying 9    Qualifications Based Selection Act.10        (g) Information the disclosure of which is restricted 11    and exempted under Section 50 of the Illinois Prepaid 12    Tuition Act.13        (h) Information the disclosure of which is exempted 14    under the State Officials and Employees Ethics Act, and 15    records of any lawfully created State or local inspector 16    general's office that would be exempt if created or 17    obtained by an Executive Inspector General's office under 18    that Act.19        (i) Information contained in a local emergency energy 20    plan submitted to a municipality in accordance with a 21    local emergency energy plan ordinance that is adopted 22    under Section 11-21.5-5 of the Illinois Municipal Code.23        (j) Information and data concerning the distribution 24    of surcharge moneys collected and remitted by carriers 25    under the Emergency Telephone System Act.26        (k) Law enforcement officer identification information   HB3794- 3 -LRB104 10437 BAB 20512 b1    or driver identification information compiled by a law 2    enforcement agency or the Department of Transportation 3    under Section 11-212 of the Illinois Vehicle Code.4        (l) Records and information provided to a residential 5    health care facility resident sexual assault and death 6    review team or the Executive Council under the Abuse 7    Prevention Review Team Act.8        (m) Information provided to the predatory lending 9    database created pursuant to Article 3 of the Residential 10    Real Property Disclosure Act, except to the extent 11    authorized under that Article.12        (n) Defense budgets and petitions for certification of 13    compensation and expenses for court appointed trial 14    counsel as provided under Sections 10 and 15 of the 15    Capital Crimes Litigation Act (repealed). This subsection 16    (n) shall apply until the conclusion of the trial of the 17    case, even if the prosecution chooses not to pursue the 18    death penalty prior to trial or sentencing.19        (o) Information that is prohibited from being 20    disclosed under Section 4 of the Illinois Health and 21    Hazardous Substances Registry Act.22        (p) Security portions of system safety program plans, 23    investigation reports, surveys, schedules, lists, data, or 24    information compiled, collected, or prepared by or for the 25    Department of Transportation under Sections 2705-300 and 26    2705-616 of the Department of Transportation Law of the   HB3794- 4 -LRB104 10437 BAB 20512 b1    Civil Administrative Code of Illinois, the Regional 2    Transportation Authority under Section 2.11 of the 3    Regional Transportation Authority Act, or the St. Clair 4    County Transit District under the Bi-State Transit Safety 5    Act (repealed). 6        (q) Information prohibited from being disclosed by the 7    Personnel Record Review Act. 8        (r) Information prohibited from being disclosed by the 9    Illinois School Student Records Act. 10        (s) Information the disclosure of which is restricted 11    under Section 5-108 of the Public Utilities Act. 12        (t) (Blank). 13        (u) Records and information provided to an independent 14    team of experts under the Developmental Disability and 15    Mental Health Safety Act (also known as Brian's Law). 16        (v) Names and information of people who have applied 17    for or received Firearm Owner's Identification Cards under 18    the Firearm Owners Identification Card Act or applied for 19    or received a concealed carry license under the Firearm 20    Concealed Carry Act, unless otherwise authorized by the 21    Firearm Concealed Carry Act; and databases under the 22    Firearm Concealed Carry Act, records of the Concealed 23    Carry Licensing Review Board under the Firearm Concealed 24    Carry Act, and law enforcement agency objections under the 25    Firearm Concealed Carry Act. 26        (v-5) Records of the Firearm Owner's Identification   HB3794- 5 -LRB104 10437 BAB 20512 b1    Card Review Board that are exempted from disclosure under 2    Section 10 of the Firearm Owners Identification Card Act.3        (w) Personally identifiable information which is 4    exempted from disclosure under subsection (g) of Section 5    19.1 of the Toll Highway Act.6        (x) Information which is exempted from disclosure 7    under Section 5-1014.3 of the Counties Code or Section 8    8-11-21 of the Illinois Municipal Code. 9        (y) Confidential information under the Adult 10    Protective Services Act and its predecessor enabling 11    statute, the Elder Abuse and Neglect Act, including 12    information about the identity and administrative finding 13    against any caregiver of a verified and substantiated 14    decision of abuse, neglect, or financial exploitation of 15    an eligible adult maintained in the Registry established 16    under Section 7.5 of the Adult Protective Services Act. 17        (z) Records and information provided to a fatality 18    review team or the Illinois Fatality Review Team Advisory 19    Council under Section 15 of the Adult Protective Services 20    Act. 21        (aa) Information which is exempted from disclosure 22    under Section 2.37 of the Wildlife Code. 23        (bb) Information which is or was prohibited from 24    disclosure by the Juvenile Court Act of 1987. 25        (cc) Recordings made under the Law Enforcement 26    Officer-Worn Body Camera Act, except to the extent   HB3794- 6 -LRB104 10437 BAB 20512 b1    authorized under that Act.2        (dd) Information that is prohibited from being 3    disclosed under Section 45 of the Condominium and Common 4    Interest Community Ombudsperson Act. 5        (ee) Information that is exempted from disclosure 6    under Section 30.1 of the Pharmacy Practice Act. 7        (ff) Information that is exempted from disclosure 8    under the Revised Uniform Unclaimed Property Act. 9        (gg) Information that is prohibited from being 10    disclosed under Section 7-603.5 of the Illinois Vehicle 11    Code. 12        (hh) Records that are exempt from disclosure under 13    Section 1A-16.7 of the Election Code. 14        (ii) Information which is exempted from disclosure 15    under Section 2505-800 of the Department of Revenue Law of 16    the Civil Administrative Code of Illinois. 17        (jj) Information and reports that are required to be 18    submitted to the Department of Labor by registering day 19    and temporary labor service agencies but are exempt from 20    disclosure under subsection (a-1) of Section 45 of the Day 21    and Temporary Labor Services Act. 22        (kk) Information prohibited from disclosure under the 23    Seizure and Forfeiture Reporting Act. 24        (ll) Information the disclosure of which is restricted 25    and exempted under Section 5-30.8 of the Illinois Public 26    Aid Code.   HB3794- 7 -LRB104 10437 BAB 20512 b1        (mm) Records that are exempt from disclosure under 2    Section 4.2 of the Crime Victims Compensation Act. 3        (nn) Information that is exempt from disclosure under 4    Section 70 of the Higher Education Student Assistance Act. 5        (oo) Communications, notes, records, and reports 6    arising out of a peer support counseling session 7    prohibited from disclosure under the First Responders 8    Suicide Prevention Act. 9        (pp) Names and all identifying information relating to 10    an employee of an emergency services provider or law 11    enforcement agency under the First Responders Suicide 12    Prevention Act. 13        (qq) Information and records held by the Department of 14    Public Health and its authorized representatives collected 15    under the Reproductive Health Act. 16        (rr) Information that is exempt from disclosure under 17    the Cannabis Regulation and Tax Act. 18        (ss) Data reported by an employer to the Department of 19    Human Rights pursuant to Section 2-108 of the Illinois 20    Human Rights Act.21        (tt) Recordings made under the Children's Advocacy 22    Center Act, except to the extent authorized under that 23    Act. 24        (uu) Information that is exempt from disclosure under 25    Section 50 of the Sexual Assault Evidence Submission Act. 26        (vv) Information that is exempt from disclosure under   HB3794- 8 -LRB104 10437 BAB 20512 b1    subsections (f) and (j) of Section 5-36 of the Illinois 2    Public Aid Code. 3        (ww) Information that is exempt from disclosure under 4    Section 16.8 of the State Treasurer Act. 5        (xx) Information that is exempt from disclosure or 6    information that shall not be made public under the 7    Illinois Insurance Code. 8        (yy) Information prohibited from being disclosed under 9    the Illinois Educational Labor Relations Act.10        (zz) Information prohibited from being disclosed under 11    the Illinois Public Labor Relations Act. 12        (aaa) Information prohibited from being disclosed 13    under Section 1-167 of the Illinois Pension Code. 14        (bbb) Information that is prohibited from disclosure 15    by the Illinois Police Training Act and the Illinois State 16    Police Act. 17        (ccc) Records exempt from disclosure under Section 18    2605-304 of the Illinois State Police Law of the Civil 19    Administrative Code of Illinois. 20        (ddd) Information prohibited from being disclosed 21    under Section 35 of the Address Confidentiality for 22    Victims of Domestic Violence, Sexual Assault, Human 23    Trafficking, or Stalking Act. 24        (eee) Information prohibited from being disclosed 25    under subsection (b) of Section 75 of the Domestic 26    Violence Fatality Review Act.   HB3794- 9 -LRB104 10437 BAB 20512 b1        (fff) Images from cameras under the Expressway Camera 2    Act. This subsection (fff) is inoperative on and after 3    July 1, 2025. 4        (ggg) Information prohibited from disclosure under 5    paragraph (3) of subsection (a) of Section 14 of the Nurse 6    Agency Licensing Act. 7        (hhh) Information submitted to the Illinois State 8    Police in an affidavit or application for an assault 9    weapon endorsement, assault weapon attachment endorsement, 10    .50 caliber rifle endorsement, or .50 caliber cartridge 11    endorsement under the Firearm Owners Identification Card 12    Act. 13        (iii) Data exempt from disclosure under Section 50 of 14    the School Safety Drill Act. 15        (jjj) Information exempt from disclosure under Section 16    30 of the Insurance Data Security Law. 17        (kkk) Confidential business information prohibited 18    from disclosure under Section 45 of the Paint Stewardship 19    Act. 20        (lll) Data exempt from disclosure under Section 21    2-3.196 of the School Code. 22        (mmm) Information prohibited from being disclosed 23    under subsection (e) of Section 1-129 of the Illinois 24    Power Agency Act. 25        (nnn) Materials received by the Department of Commerce 26    and Economic Opportunity that are confidential under the   HB3794- 10 -LRB104 10437 BAB 20512 b1    Music and Musicians Tax Credit and Jobs Act. 2        (ooo) (nnn) Data or information provided pursuant to 3    Section 20 of the Statewide Recycling Needs and Assessment 4    Act. 5        (ppp) (nnn) Information that is exempt from disclosure 6    under Section 28-11 of the Lawful Health Care Activity 7    Act. 8        (qqq) (nnn) Information that is exempt from disclosure 9    under Section 7-101 of the Illinois Human Rights Act. 10        (rrr) (mmm) Information prohibited from being 11    disclosed under Section 4-2 of the Uniform Money 12    Transmission Modernization Act. 13        (sss) (nnn) Information exempt from disclosure under 14    Section 40 of the Student-Athlete Endorsement Rights Act.15        (ttt) Information prohibited from being disclosed 16    under subsection (g-5) of Section 513b1 of the Illinois 17    Insurance Code. 18(Source: P.A. 102-36, eff. 6-25-21; 102-237, eff. 1-1-22; 19102-292, eff. 1-1-22; 102-520, eff. 8-20-21; 102-559, eff. 208-20-21; 102-813, eff. 5-13-22; 102-946, eff. 7-1-22; 21102-1042, eff. 6-3-22; 102-1116, eff. 1-10-23; 103-8, eff. 226-7-23; 103-34, eff. 6-9-23; 103-142, eff. 1-1-24; 103-372, 23eff. 1-1-24; 103-472, eff. 8-1-24; 103-508, eff. 8-4-23; 24103-580, eff. 12-8-23; 103-592, eff. 6-7-24; 103-605, eff. 257-1-24; 103-636, eff. 7-1-24; 103-724, eff. 1-1-25; 103-786, 26eff. 8-7-24; 103-859, eff. 8-9-24; 103-991, eff. 8-9-24;   HB3794- 11 -LRB104 10437 BAB 20512 b1103-1049, eff. 8-9-24; revised 11-26-24.) 2    Section 10. The Illinois Insurance Code is amended by 3changing Section 513b1 as follows: 4    (215 ILCS 5/513b1)5    Sec. 513b1. Pharmacy benefit manager contracts.6    (a) As used in this Section: 7    "340B drug discount program" means the program established 8under Section 340B of the federal Public Health Service Act, 942 U.S.C. 256b. 10    "340B entity" means a covered entity as defined in 42 11U.S.C. 256b(a)(4) authorized to participate in the 340B drug 12discount program. 13    "340B pharmacy" means any pharmacy used to dispense 340B 14drugs for a covered entity, whether entity-owned or external. 15    "Biological product" has the meaning ascribed to that term 16in Section 19.5 of the Pharmacy Practice Act.17    "Defined cost sharing" means a deductible payment or 18coinsurance amount imposed on an enrollee for a covered 19prescription drug under the enrollee's health benefit plan. 20    "Maximum allowable cost" means the maximum amount that a 21pharmacy benefit manager will reimburse a pharmacy for the 22cost of a drug. 23    "Maximum allowable cost list" means a list of drugs for 24which a maximum allowable cost has been established by a   HB3794- 12 -LRB104 10437 BAB 20512 b1pharmacy benefit manager. 2    "Pharmacy benefit manager" means a person, business, or 3entity, including a wholly or partially owned or controlled 4subsidiary of a pharmacy benefit manager, that provides claims 5processing services or other prescription drug or device 6services, or both, for health benefit plans. 7    "Price protection rebate" means a negotiated price 8concession that accrues directly or indirectly to a health 9insurer, or other party on behalf of the health insurer, if 10there is an increase in the wholesale acquisition cost of a 11prescription drug above a specified threshold.12    "Rebate" means:13        (1) a negotiated price concession, including, without 14    limitation, base price concessions, whether described as a 15    rebate or not, reasonable estimates of any price 16    protection rebates, or performance-based price concessions 17    that may accrue, directly or indirectly, to the health 18    insurer during the coverage year from a manufacturer or 19    other party in connection with the dispensing or 20    administration of a prescription drug; or21        (2) any reasonable estimate of a negotiated price 22    concession, fee, or other administrative cost that is 23    passed through, or is reasonably anticipated to be passed 24    through, to the health insurer and serves to reduce the 25    health insurer's liabilities for a prescription drug. 26    "Retail price" means the price an individual without   HB3794- 13 -LRB104 10437 BAB 20512 b1prescription drug coverage would pay at a retail pharmacy, not 2including a pharmacist dispensing fee. 3    "Third-party payer" means any entity that pays for 4prescription drugs on behalf of a patient other than a health 5care provider or sponsor of a plan subject to regulation under 6Medicare Part D, 42 U.S.C. 1395w-101 et seq. 7    (b) A contract between a health insurer and a pharmacy 8benefit manager must require that the pharmacy benefit 9manager: 10        (1) Update maximum allowable cost pricing information 11    at least every 7 calendar days. 12        (2) Maintain a process that will, in a timely manner, 13    eliminate drugs from maximum allowable cost lists or 14    modify drug prices to remain consistent with changes in 15    pricing data used in formulating maximum allowable cost 16    prices and product availability. 17        (3) Provide access to its maximum allowable cost list 18    to each pharmacy or pharmacy services administrative 19    organization subject to the maximum allowable cost list. 20    Access may include a real-time pharmacy website portal to 21    be able to view the maximum allowable cost list. As used in 22    this Section, "pharmacy services administrative 23    organization" means an entity operating within the State 24    that contracts with independent pharmacies to conduct 25    business on their behalf with third-party payers. A 26    pharmacy services administrative organization may provide   HB3794- 14 -LRB104 10437 BAB 20512 b1    administrative services to pharmacies and negotiate and 2    enter into contracts with third-party payers or pharmacy 3    benefit managers on behalf of pharmacies. 4        (4) Provide a process by which a contracted pharmacy 5    can appeal the provider's reimbursement for a drug subject 6    to maximum allowable cost pricing. The appeals process 7    must, at a minimum, include the following: 8            (A) A requirement that a contracted pharmacy has 9        14 calendar days after the applicable fill date to 10        appeal a maximum allowable cost if the reimbursement 11        for the drug is less than the net amount that the 12        network provider paid to the supplier of the drug. 13            (B) A requirement that a pharmacy benefit manager 14        must respond to a challenge within 14 calendar days of 15        the contracted pharmacy making the claim for which the 16        appeal has been submitted.17            (C) A telephone number and e-mail address or 18        website to network providers, at which the provider 19        can contact the pharmacy benefit manager to process 20        and submit an appeal.21            (D) A requirement that, if an appeal is denied, 22        the pharmacy benefit manager must provide the reason 23        for the denial and the name and the national drug code 24        number from national or regional wholesalers.25            (E) A requirement that, if an appeal is sustained, 26        the pharmacy benefit manager must make an adjustment   HB3794- 15 -LRB104 10437 BAB 20512 b1        in the drug price effective the date the challenge is 2        resolved and make the adjustment applicable to all 3        similarly situated network pharmacy providers, as 4        determined by the managed care organization or 5        pharmacy benefit manager. 6        (5) Allow a plan sponsor contracting with a pharmacy 7    benefit manager an annual right to audit compliance with 8    the terms of the contract by the pharmacy benefit manager, 9    including, but not limited to, full disclosure of any and 10    all rebate amounts secured, whether product specific or 11    generalized rebates, that were provided to the pharmacy 12    benefit manager by a pharmaceutical manufacturer.13        (6) Allow a plan sponsor contracting with a pharmacy 14    benefit manager to request that the pharmacy benefit 15    manager disclose the actual amounts paid by the pharmacy 16    benefit manager to the pharmacy.17        (7) Provide notice to the party contracting with the 18    pharmacy benefit manager of any consideration that the 19    pharmacy benefit manager receives from the manufacturer 20    for dispense as written prescriptions once a generic or 21    biologically similar product becomes available. 22    (c) In order to place a particular prescription drug on a 23maximum allowable cost list, the pharmacy benefit manager 24must, at a minimum, ensure that: 25        (1) if the drug is a generically equivalent drug, it 26    is listed as therapeutically equivalent and   HB3794- 16 -LRB104 10437 BAB 20512 b1    pharmaceutically equivalent "A" or "B" rated in the United 2    States Food and Drug Administration's most recent version 3    of the "Orange Book" or have an NR or NA rating by 4    Medi-Span, Gold Standard, or a similar rating by a 5    nationally recognized reference; 6        (2) the drug is available for purchase by each 7    pharmacy in the State from national or regional 8    wholesalers operating in Illinois; and 9        (3) the drug is not obsolete. 10    (d) A pharmacy benefit manager is prohibited from limiting 11a pharmacist's ability to disclose whether the cost-sharing 12obligation exceeds the retail price for a covered prescription 13drug, and the availability of a more affordable alternative 14drug, if one is available in accordance with Section 42 of the 15Pharmacy Practice Act. 16    (e) A health insurer or pharmacy benefit manager shall not 17require an insured to make a payment for a prescription drug at 18the point of sale in an amount that exceeds the lesser of: 19        (1) the applicable cost-sharing amount; or20        (2) the retail price of the drug in the absence of 21    prescription drug coverage. 22    (f) Unless required by law, a contract between a pharmacy 23benefit manager or third-party payer and a 340B entity or 340B 24pharmacy shall not contain any provision that: 25        (1) distinguishes between drugs purchased through the 26    340B drug discount program and other drugs when   HB3794- 17 -LRB104 10437 BAB 20512 b1    determining reimbursement or reimbursement methodologies, 2    or contains otherwise less favorable payment terms or 3    reimbursement methodologies for 340B entities or 340B 4    pharmacies when compared to similarly situated non-340B 5    entities; 6        (2) imposes any fee, chargeback, or rate adjustment 7    that is not similarly imposed on similarly situated 8    pharmacies that are not 340B entities or 340B pharmacies; 9        (3) imposes any fee, chargeback, or rate adjustment 10    that exceeds the fee, chargeback, or rate adjustment that 11    is not similarly imposed on similarly situated pharmacies 12    that are not 340B entities or 340B pharmacies; 13        (4) prevents or interferes with an individual's choice 14    to receive a covered prescription drug from a 340B entity 15    or 340B pharmacy through any legally permissible means, 16    except that nothing in this paragraph shall prohibit the 17    establishment of differing copayments or other 18    cost-sharing amounts within the benefit plan for covered 19    persons who acquire covered prescription drugs from a 20    nonpreferred or nonparticipating provider; 21        (5) excludes a 340B entity or 340B pharmacy from a 22    pharmacy network on any basis that includes consideration 23    of whether the 340B entity or 340B pharmacy participates 24    in the 340B drug discount program; 25        (6) prevents a 340B entity or 340B pharmacy from using 26    a drug purchased under the 340B drug discount program; or   HB3794- 18 -LRB104 10437 BAB 20512 b1        (7) any other provision that discriminates against a 2    340B entity or 340B pharmacy by treating the 340B entity 3    or 340B pharmacy differently than non-340B entities or 4    non-340B pharmacies for any reason relating to the 5    entity's participation in the 340B drug discount program.6     (g-5) A covered individual's defined cost sharing for 7each prescription drug shall be calculated at the point of 8sale based on a price that is reduced by an amount equal to at 9least 80% of all rebates received or to be received in 10connection with the dispensing or administration of the 11prescription drug.12    In complying with this Section, a health insurer or its 13agents shall not publish or otherwise reveal information 14regarding the actual amount of rebates a health insurer 15receives on a product or therapeutic class of products, 16manufacturer-specific basis, or pharmacy-specific basis. The 17information described in this subsection is: (i) considered 18protected as a trade secret; (ii) considered proprietary and 19confidential; (iii) not subject to disclosure under the 20federal Freedom of Information Act or the Freedom of 21Information Act; and (iv) not to be disclosed directly, 22indirectly, or in a manner that would either allow for the 23identification of an individual product, therapeutic class of 24products, or manufacturer or have the potential to compromise 25the financial, competitive, or proprietary nature of the 26information. A health insurer shall impose the confidentiality   HB3794- 19 -LRB104 10437 BAB 20512 b1protections of this subsection on any vendor or other third 2party that performs health care or administrative services on 3behalf of the health insurer that may receive or have access to 4rebate information. 5    Nothing in this subsection precludes a pharmacy benefit 6manager or insurer from reducing an insured's cost sharing by 7an amount greater than that required under this subsection.8    As used in this subsection, "pharmacy benefit manager" and 9"third-party payer" do not include pharmacy benefit managers 10and third-party payers acting on behalf of a Medicaid program. 11    (g) A violation of this Section by a pharmacy benefit 12manager constitutes an unfair or deceptive act or practice in 13the business of insurance under Section 424. 14    (h) A provision that violates subsection (f) in a contract 15between a pharmacy benefit manager or a third-party payer and 16a 340B entity that is entered into, amended, or renewed after 17July 1, 2022 shall be void and unenforceable. 18    (i)(1) A pharmacy benefit manager may not retaliate 19against a pharmacist or pharmacy for disclosing information in 20a court, in an administrative hearing, before a legislative 21commission or committee, or in any other proceeding, if the 22pharmacist or pharmacy has reasonable cause to believe that 23the disclosed information is evidence of a violation of a 24State or federal law, rule, or regulation.25    (2) A pharmacy benefit manager may not retaliate against a 26pharmacist or pharmacy for disclosing information to a   HB3794- 20 -LRB104 10437 BAB 20512 b1government or law enforcement agency, if the pharmacist or 2pharmacy has reasonable cause to believe that the disclosed 3information is evidence of a violation of a State or federal 4law, rule, or regulation.5    (3) A pharmacist or pharmacy shall make commercially 6reasonable efforts to limit the disclosure of confidential and 7proprietary information.8    (4) Retaliatory actions against a pharmacy or pharmacist 9include cancellation of, restriction of, or refusal to renew 10or offer a contract to a pharmacy solely because the pharmacy 11or pharmacist has:12        (A) made disclosures of information that the 13    pharmacist or pharmacy has reasonable cause to believe is 14    evidence of a violation of a State or federal law, rule, or 15    regulation;16        (B) filed complaints with the plan or pharmacy benefit 17    manager; or18        (C) filed complaints against the plan or pharmacy 19    benefit manager with the Department.20    (j) This Section applies to contracts entered into or 21renewed on or after July 1, 2022, except that subsection (g-5) 22applies to contracts entered into or renewed on or after 23January 1, 2026. 24    (k) This Section applies to any group or individual policy 25of accident and health insurance or managed care plan that 26provides coverage for prescription drugs and that is amended,   HB3794- 21 -LRB104 10437 BAB 20512 b1delivered, issued, or renewed on or after July 1, 2020. 2(Source: P.A. 102-778, eff. 7-1-22; 103-154, eff. 6-30-23; 3103-453, eff. 8-4-23.) 4    Section 15. The Pharmacy Practice Act is amended by 5changing Section 19.5 as follows: 6    (225 ILCS 85/19.5)7    (Section scheduled to be repealed on January 1, 2028)8    Sec. 19.5. Biological products.9    (a) For the purposes of this Section:10    "Biological product" has the meaning given to that term in 1142 U.S.C. 262.12    "Interchangeable biological product" means a biological 13product that the United States Food and Drug Administration:14        (1) has (A) licensed and (B) determined it to meet the 15    standards for interchangeability pursuant to 42 U.S.C. 16    262(k)(4); or 17        (2) has determined is therapeutically equivalent as 18    set forth in the latest edition of or supplement to the 19    United States Food and Drug Administration's Approved Drug 20    Products with Therapeutic Equivalence Evaluations (Orange 21    Book).22    (b) A pharmacist may substitute a an interchangeable 23biological product for a prescribed biological product only if 24all of the following conditions in this subsection (b) are   HB3794- 22 -LRB104 10437 BAB 20512 b1met:2        (1) the product being considered for substitution is 3    either the reference product or a product approved by the 4    United States Food and Drug Administration as a biosimilar 5    of the prescribed biological product; the substituted 6    product has been determined by the United States Food and 7    Drug Administration to be interchangeable, as defined in 8    subsection (a) of this Section, with the prescribed 9    biological product;10        (2) the prescribing physician does not designate 11    orally, in writing, or electronically that substitution is 12    prohibited in a manner consistent with Section 25 of this 13    Act; and14        (3) the pharmacy informs the patient of the 15    substitution.16    (c) Within 5 business days following the dispensing of a 17biological product, the dispensing pharmacist or the 18pharmacist's designee shall make an entry of the specific 19product provided to the patient, including the name of the 20product and the manufacturer. The communication shall be 21conveyed by making an entry that can be electronically 22accessed by the prescriber through:23        (1) an interoperable electronic medical records 24    system;25        (2) an electronic prescribing technology;26        (3) a pharmacy benefit management system; or   HB3794- 23 -LRB104 10437 BAB 20512 b1        (4) a pharmacy record. 2    Entry into an electronic records system as described in 3this subsection (c) is presumed to provide notice in 4accordance with this subsection (c). Otherwise, the pharmacist 5shall communicate the biological product dispensed to the 6prescriber using facsimile, telephone, electronic 7transmission, or other prevailing means, except that 8communication shall not be required if where: (A) there is no 9United States Food and Drug Administration-approved 10interchangeable biological product for the product prescribed; 11or (B) a refill prescription is not changed from the product 12dispensed on the prior filling of the prescription. 13    (d) The pharmacy shall retain a record of the biological 14product dispensed for a period of 5 years.15    (e) (Blank). The Department shall maintain a link on its 16Internet website to the current list of all biological 17products determined by the United States Food and Drug 18Administration to be interchangeable with a specific 19biological product.20    (f) The Department may adopt rules for compliance with 21this Section.22(Source: P.A. 99-200, eff. 1-1-16.)


================================================================================

Raw Text:
Full Text of HB3794 ILGA.GOV HB3794 - 104th General Assembly 104TH GENERAL ASSEMBLY State of Illinois 2025 and 2026HB3794 Introduced 2/18/2025, by Rep. Ryan Spain SYNOPSIS AS INTRODUCED: 5 ILCS 140/7.5215 ILCS 5/513b1225 ILCS 85/19.5    Amends the Pharmacy Benefit Manager Article of the Illinois Insurance Code. Provides that a covered individual's defined cost sharing for each prescription drug shall be calculated at the point of sale based on a price that is reduced by an amount equal to at least 80% of all rebates received, or to be received, or to be received, in connection with the dispensing or administration of the prescription drug. Provides that a health insurer or its agents shall not publish or otherwise reveal information regarding the actual amount of rebates a health insurer receives on a product or therapeutic class of products, manufacturer-specific basis, or pharmacy-specific basis and that the information is confidential. Defines terms. Amends the Freedom of Information Act to make a conforming change. Amends the Pharmacy Practice Act. Provides that a pharmacist may substitute a biological product (instead of an interchangeable biological product) if, among other requirements, the product being considered for substitution is either the reference product or a product approved by the United States Food and Drug Administration as a biosimilar of the prescribed biological product (instead of if the substituted product has been determined by the United States Food and Drug Administration to be interchangeable with the prescribed biological product). Makes conforming changes. LRB104 10437 BAB 20512 b  A BILL FOR HB3794LRB104 10437 BAB 20512 b1    AN ACT concerning prescription drugs. 2    Be it enacted by the People of the State of Illinois, 3represented in the General Assembly: 4    Section 5. The Freedom of Information Act is amended by 5changing Section 7.5 as follows: 6    (5 ILCS 140/7.5)7    Sec. 7.5. Statutory exemptions. To the extent provided for 8by the statutes referenced below, the following shall be 9exempt from inspection and copying:10        (a) All information determined to be confidential 11    under Section 4002 of the Technology Advancement and 12    Development Act.13        (b) Library circulation and order records identifying 14    library users with specific materials under the Library 15    Records Confidentiality Act.16        (c) Applications, related documents, and medical 17    records received by the Experimental Organ Transplantation 18    Procedures Board and any and all documents or other 19    records prepared by the Experimental Organ Transplantation 20    Procedures Board or its staff relating to applications it 21    has received.22        (d) Information and records held by the Department of 23    Public Health and its authorized representatives relating   HB3794- 2 -LRB104 10437 BAB 20512 b1    to known or suspected cases of sexually transmitted 2    infection or any information the disclosure of which is 3    restricted under the Illinois Sexually Transmitted 4    Infection Control Act.5        (e) Information the disclosure of which is exempted 6    under Section 30 of the Radon Industry Licensing Act.7        (f) Firm performance evaluations under Section 55 of 8    the Architectural, Engineering, and Land Surveying 9    Qualifications Based Selection Act.10        (g) Information the disclosure of which is restricted 11    and exempted under Section 50 of the Illinois Prepaid 12    Tuition Act.13        (h) Information the disclosure of which is exempted 14    under the State Officials and Employees Ethics Act, and 15    records of any lawfully created State or local inspector 16    general's office that would be exempt if created or 17    obtained by an Executive Inspector General's office under 18    that Act.19        (i) Information contained in a local emergency energy 20    plan submitted to a municipality in accordance with a 21    local emergency energy plan ordinance that is adopted 22    under Section 11-21.5-5 of the Illinois Municipal Code.23        (j) Information and data concerning the distribution 24    of surcharge moneys collected and remitted by carriers 25    under the Emergency Telephone System Act.26        (k) Law enforcement officer identification information   HB3794- 3 -LRB104 10437 BAB 20512 b1    or driver identification information compiled by a law 2    enforcement agency or the Department of Transportation 3    under Section 11-212 of the Illinois Vehicle Code.4        (l) Records and information provided to a residential 5    health care facility resident sexual assault and death 6    review team or the Executive Council under the Abuse 7    Prevention Review Team Act.8        (m) Information provided to the predatory lending 9    database created pursuant to Article 3 of the Residential 10    Real Property Disclosure Act, except to the extent 11    authorized under that Article.12        (n) Defense budgets and petitions for certification of 13    compensation and expenses for court appointed trial 14    counsel as provided under Sections 10 and 15 of the 15    Capital Crimes Litigation Act (repealed). This subsection 16    (n) shall apply until the conclusion of the trial of the 17    case, even if the prosecution chooses not to pursue the 18    death penalty prior to trial or sentencing.19        (o) Information that is prohibited from being 20    disclosed under Section 4 of the Illinois Health and 21    Hazardous Substances Registry Act.22        (p) Security portions of system safety program plans, 23    investigation reports, surveys, schedules, lists, data, or 24    information compiled, collected, or prepared by or for the 25    Department of Transportation under Sections 2705-300 and 26    2705-616 of the Department of Transportation Law of the   HB3794- 4 -LRB104 10437 BAB 20512 b1    Civil Administrative Code of Illinois, the Regional 2    Transportation Authority under Section 2.11 of the 3    Regional Transportation Authority Act, or the St. Clair 4    County Transit District under the Bi-State Transit Safety 5    Act (repealed). 6        (q) Information prohibited from being disclosed by the 7    Personnel Record Review Act. 8        (r) Information prohibited from being disclosed by the 9    Illinois School Student Records Act. 10        (s) Information the disclosure of which is restricted 11    under Section 5-108 of the Public Utilities Act. 12        (t) (Blank). 13        (u) Records and information provided to an independent 14    team of experts under the Developmental Disability and 15    Mental Health Safety Act (also known as Brian's Law). 16        (v) Names and information of people who have applied 17    for or received Firearm Owner's Identification Cards under 18    the Firearm Owners Identification Card Act or applied for 19    or received a concealed carry license under the Firearm 20    Concealed Carry Act, unless otherwise authorized by the 21    Firearm Concealed Carry Act; and databases under the 22    Firearm Concealed Carry Act, records of the Concealed 23    Carry Licensing Review Board under the Firearm Concealed 24    Carry Act, and law enforcement agency objections under the 25    Firearm Concealed Carry Act. 26        (v-5) Records of the Firearm Owner's Identification   HB3794- 5 -LRB104 10437 BAB 20512 b1    Card Review Board that are exempted from disclosure under 2    Section 10 of the Firearm Owners Identification Card Act.3        (w) Personally identifiable information which is 4    exempted from disclosure under subsection (g) of Section 5    19.1 of the Toll Highway Act.6        (x) Information which is exempted from disclosure 7    under Section 5-1014.3 of the Counties Code or Section 8    8-11-21 of the Illinois Municipal Code. 9        (y) Confidential information under the Adult 10    Protective Services Act and its predecessor enabling 11    statute, the Elder Abuse and Neglect Act, including 12    information about the identity and administrative finding 13    against any caregiver of a verified and substantiated 14    decision of abuse, neglect, or financial exploitation of 15    an eligible adult maintained in the Registry established 16    under Section 7.5 of the Adult Protective Services Act. 17        (z) Records and information provided to a fatality 18    review team or the Illinois Fatality Review Team Advisory 19    Council under Section 15 of the Adult Protective Services 20    Act. 21        (aa) Information which is exempted from disclosure 22    under Section 2.37 of the Wildlife Code. 23        (bb) Information which is or was prohibited from 24    disclosure by the Juvenile Court Act of 1987. 25        (cc) Recordings made under the Law Enforcement 26    Officer-Worn Body Camera Act, except to the extent   HB3794- 6 -LRB104 10437 BAB 20512 b1    authorized under that Act.2        (dd) Information that is prohibited from being 3    disclosed under Section 45 of the Condominium and Common 4    Interest Community Ombudsperson Act. 5        (ee) Information that is exempted from disclosure 6    under Section 30.1 of the Pharmacy Practice Act. 7        (ff) Information that is exempted from disclosure 8    under the Revised Uniform Unclaimed Property Act. 9        (gg) Information that is prohibited from being 10    disclosed under Section 7-603.5 of the Illinois Vehicle 11    Code. 12        (hh) Records that are exempt from disclosure under 13    Section 1A-16.7 of the Election Code. 14        (ii) Information which is exempted from disclosure 15    under Section 2505-800 of the Department of Revenue Law of 16    the Civil Administrative Code of Illinois. 17        (jj) Information and reports that are required to be 18    submitted to the Department of Labor by registering day 19    and temporary labor service agencies but are exempt from 20    disclosure under subsection (a-1) of Section 45 of the Day 21    and Temporary Labor Services Act. 22        (kk) Information prohibited from disclosure under the 23    Seizure and Forfeiture Reporting Act. 24        (ll) Information the disclosure of which is restricted 25    and exempted under Section 5-30.8 of the Illinois Public 26    Aid Code.   HB3794- 7 -LRB104 10437 BAB 20512 b1        (mm) Records that are exempt from disclosure under 2    Section 4.2 of the Crime Victims Compensation Act. 3        (nn) Information that is exempt from disclosure under 4    Section 70 of the Higher Education Student Assistance Act. 5        (oo) Communications, notes, records, and reports 6    arising out of a peer support counseling session 7    prohibited from disclosure under the First Responders 8    Suicide Prevention Act. 9        (pp) Names and all identifying information relating to 10    an employee of an emergency services provider or law 11    enforcement agency under the First Responders Suicide 12    Prevention Act. 13        (qq) Information and records held by the Department of 14    Public Health and its authorized representatives collected 15    under the Reproductive Health Act. 16        (rr) Information that is exempt from disclosure under 17    the Cannabis Regulation and Tax Act. 18        (ss) Data reported by an employer to the Department of 19    Human Rights pursuant to Section 2-108 of the Illinois 20    Human Rights Act.21        (tt) Recordings made under the Children's Advocacy 22    Center Act, except to the extent authorized under that 23    Act. 24        (uu) Information that is exempt from disclosure under 25    Section 50 of the Sexual Assault Evidence Submission Act. 26        (vv) Information that is exempt from disclosure under   HB3794- 8 -LRB104 10437 BAB 20512 b1    subsections (f) and (j) of Section 5-36 of the Illinois 2    Public Aid Code. 3        (ww) Information that is exempt from disclosure under 4    Section 16.8 of the State Treasurer Act. 5        (xx) Information that is exempt from disclosure or 6    information that shall not be made public under the 7    Illinois Insurance Code. 8        (yy) Information prohibited from being disclosed under 9    the Illinois Educational Labor Relations Act.10        (zz) Information prohibited from being disclosed under 11    the Illinois Public Labor Relations Act. 12        (aaa) Information prohibited from being disclosed 13    under Section 1-167 of the Illinois Pension Code. 14        (bbb) Information that is prohibited from disclosure 15    by the Illinois Police Training Act and the Illinois State 16    Police Act. 17        (ccc) Records exempt from disclosure under Section 18    2605-304 of the Illinois State Police Law of the Civil 19    Administrative Code of Illinois. 20        (ddd) Information prohibited from being disclosed 21    under Section 35 of the Address Confidentiality for 22    Victims of Domestic Violence, Sexual Assault, Human 23    Trafficking, or Stalking Act. 24        (eee) Information prohibited from being disclosed 25    under subsection (b) of Section 75 of the Domestic 26    Violence Fatality Review Act.   HB3794- 9 -LRB104 10437 BAB 20512 b1        (fff) Images from cameras under the Expressway Camera 2    Act. This subsection (fff) is inoperative on and after 3    July 1, 2025. 4        (ggg) Information prohibited from disclosure under 5    paragraph (3) of subsection (a) of Section 14 of the Nurse 6    Agency Licensing Act. 7        (hhh) Information submitted to the Illinois State 8    Police in an affidavit or application for an assault 9    weapon endorsement, assault weapon attachment endorsement, 10    .50 caliber rifle endorsement, or .50 caliber cartridge 11    endorsement under the Firearm Owners Identification Card 12    Act. 13        (iii) Data exempt from disclosure under Section 50 of 14    the School Safety Drill Act. 15        (jjj) Information exempt from disclosure under Section 16    30 of the Insurance Data Security Law. 17        (kkk) Confidential business information prohibited 18    from disclosure under Section 45 of the Paint Stewardship 19    Act. 20        (lll) Data exempt from disclosure under Section 21    2-3.196 of the School Code. 22        (mmm) Information prohibited from being disclosed 23    under subsection (e) of Section 1-129 of the Illinois 24    Power Agency Act. 25        (nnn) Materials received by the Department of Commerce 26    and Economic Opportunity that are confidential under the   HB3794- 10 -LRB104 10437 BAB 20512 b1    Music and Musicians Tax Credit and Jobs Act. 2        (ooo) (nnn) Data or information provided pursuant to 3    Section 20 of the Statewide Recycling Needs and Assessment 4    Act. 5        (ppp) (nnn) Information that is exempt from disclosure 6    under Section 28-11 of the Lawful Health Care Activity 7    Act. 8        (qqq) (nnn) Information that is exempt from disclosure 9    under Section 7-101 of the Illinois Human Rights Act. 10        (rrr) (mmm) Information prohibited from being 11    disclosed under Section 4-2 of the Uniform Money 12    Transmission Modernization Act. 13        (sss) (nnn) Information exempt from disclosure under 14    Section 40 of the Student-Athlete Endorsement Rights Act.15        (ttt) Information prohibited from being disclosed 16    under subsection (g-5) of Section 513b1 of the Illinois 17    Insurance Code. 18(Source: P.A. 102-36, eff. 6-25-21; 102-237, eff. 1-1-22; 19102-292, eff. 1-1-22; 102-520, eff. 8-20-21; 102-559, eff. 208-20-21; 102-813, eff. 5-13-22; 102-946, eff. 7-1-22; 21102-1042, eff. 6-3-22; 102-1116, eff. 1-10-23; 103-8, eff. 226-7-23; 103-34, eff. 6-9-23; 103-142, eff. 1-1-24; 103-372, 23eff. 1-1-24; 103-472, eff. 8-1-24; 103-508, eff. 8-4-23; 24103-580, eff. 12-8-23; 103-592, eff. 6-7-24; 103-605, eff. 257-1-24; 103-636, eff. 7-1-24; 103-724, eff. 1-1-25; 103-786, 26eff. 8-7-24; 103-859, eff. 8-9-24; 103-991, eff. 8-9-24;   HB3794- 11 -LRB104 10437 BAB 20512 b1103-1049, eff. 8-9-24; revised 11-26-24.) 2    Section 10. The Illinois Insurance Code is amended by 3changing Section 513b1 as follows: 4    (215 ILCS 5/513b1)5    Sec. 513b1. Pharmacy benefit manager contracts.6    (a) As used in this Section: 7    "340B drug discount program" means the program established 8under Section 340B of the federal Public Health Service Act, 942 U.S.C. 256b. 10    "340B entity" means a covered entity as defined in 42 11U.S.C. 256b(a)(4) authorized to participate in the 340B drug 12discount program. 13    "340B pharmacy" means any pharmacy used to dispense 340B 14drugs for a covered entity, whether entity-owned or external. 15    "Biological product" has the meaning ascribed to that term 16in Section 19.5 of the Pharmacy Practice Act.17    "Defined cost sharing" means a deductible payment or 18coinsurance amount imposed on an enrollee for a covered 19prescription drug under the enrollee's health benefit plan. 20    "Maximum allowable cost" means the maximum amount that a 21pharmacy benefit manager will reimburse a pharmacy for the 22cost of a drug. 23    "Maximum allowable cost list" means a list of drugs for 24which a maximum allowable cost has been established by a   HB3794- 12 -LRB104 10437 BAB 20512 b1pharmacy benefit manager. 2    "Pharmacy benefit manager" means a person, business, or 3entity, including a wholly or partially owned or controlled 4subsidiary of a pharmacy benefit manager, that provides claims 5processing services or other prescription drug or device 6services, or both, for health benefit plans. 7    "Price protection rebate" means a negotiated price 8concession that accrues directly or indirectly to a health 9insurer, or other party on behalf of the health insurer, if 10there is an increase in the wholesale acquisition cost of a 11prescription drug above a specified threshold.12    "Rebate" means:13        (1) a negotiated price concession, including, without 14    limitation, base price concessions, whether described as a 15    rebate or not, reasonable estimates of any price 16    protection rebates, or performance-based price concessions 17    that may accrue, directly or indirectly, to the health 18    insurer during the coverage year from a manufacturer or 19    other party in connection with the dispensing or 20    administration of a prescription drug; or21        (2) any reasonable estimate of a negotiated price 22    concession, fee, or other administrative cost that is 23    passed through, or is reasonably anticipated to be passed 24    through, to the health insurer and serves to reduce the 25    health insurer's liabilities for a prescription drug. 26    "Retail price" means the price an individual without   HB3794- 13 -LRB104 10437 BAB 20512 b1prescription drug coverage would pay at a retail pharmacy, not 2including a pharmacist dispensing fee. 3    "Third-party payer" means any entity that pays for 4prescription drugs on behalf of a patient other than a health 5care provider or sponsor of a plan subject to regulation under 6Medicare Part D, 42 U.S.C. 1395w-101 et seq. 7    (b) A contract between a health insurer and a pharmacy 8benefit manager must require that the pharmacy benefit 9manager: 10        (1) Update maximum allowable cost pricing information 11    at least every 7 calendar days. 12        (2) Maintain a process that will, in a timely manner, 13    eliminate drugs from maximum allowable cost lists or 14    modify drug prices to remain consistent with changes in 15    pricing data used in formulating maximum allowable cost 16    prices and product availability. 17        (3) Provide access to its maximum allowable cost list 18    to each pharmacy or pharmacy services administrative 19    organization subject to the maximum allowable cost list. 20    Access may include a real-time pharmacy website portal to 21    be able to view the maximum allowable cost list. As used in 22    this Section, "pharmacy services administrative 23    organization" means an entity operating within the State 24    that contracts with independent pharmacies to conduct 25    business on their behalf with third-party payers. A 26    pharmacy services administrative organization may provide   HB3794- 14 -LRB104 10437 BAB 20512 b1    administrative services to pharmacies and negotiate and 2    enter into contracts with third-party payers or pharmacy 3    benefit managers on behalf of pharmacies. 4        (4) Provide a process by which a contracted pharmacy 5    can appeal the provider's reimbursement for a drug subject 6    to maximum allowable cost pricing. The appeals process 7    must, at a minimum, include the following: 8            (A) A requirement that a contracted pharmacy has 9        14 calendar days after the applicable fill date to 10        appeal a maximum allowable cost if the reimbursement 11        for the drug is less than the net amount that the 12        network provider paid to the supplier of the drug. 13            (B) A requirement that a pharmacy benefit manager 14        must respond to a challenge within 14 calendar days of 15        the contracted pharmacy making the claim for which the 16        appeal has been submitted.17            (C) A telephone number and e-mail address or 18        website to network providers, at which the provider 19        can contact the pharmacy benefit manager to process 20        and submit an appeal.21            (D) A requirement that, if an appeal is denied, 22        the pharmacy benefit manager must provide the reason 23        for the denial and the name and the national drug code 24        number from national or regional wholesalers.25            (E) A requirement that, if an appeal is sustained, 26        the pharmacy benefit manager must make an adjustment   HB3794- 15 -LRB104 10437 BAB 20512 b1        in the drug price effective the date the challenge is 2        resolved and make the adjustment applicable to all 3        similarly situated network pharmacy providers, as 4        determined by the managed care organization or 5        pharmacy benefit manager. 6        (5) Allow a plan sponsor contracting with a pharmacy 7    benefit manager an annual right to audit compliance with 8    the terms of the contract by the pharmacy benefit manager, 9    including, but not limited to, full disclosure of any and 10    all rebate amounts secured, whether product specific or 11    generalized rebates, that were provided to the pharmacy 12    benefit manager by a pharmaceutical manufacturer.13        (6) Allow a plan sponsor contracting with a pharmacy 14    benefit manager to request that the pharmacy benefit 15    manager disclose the actual amounts paid by the pharmacy 16    benefit manager to the pharmacy.17        (7) Provide notice to the party contracting with the 18    pharmacy benefit manager of any consideration that the 19    pharmacy benefit manager receives from the manufacturer 20    for dispense as written prescriptions once a generic or 21    biologically similar product becomes available. 22    (c) In order to place a particular prescription drug on a 23maximum allowable cost list, the pharmacy benefit manager 24must, at a minimum, ensure that: 25        (1) if the drug is a generically equivalent drug, it 26    is listed as therapeutically equivalent and   HB3794- 16 -LRB104 10437 BAB 20512 b1    pharmaceutically equivalent "A" or "B" rated in the United 2    States Food and Drug Administration's most recent version 3    of the "Orange Book" or have an NR or NA rating by 4    Medi-Span, Gold Standard, or a similar rating by a 5    nationally recognized reference; 6        (2) the drug is available for purchase by each 7    pharmacy in the State from national or regional 8    wholesalers operating in Illinois; and 9        (3) the drug is not obsolete. 10    (d) A pharmacy benefit manager is prohibited from limiting 11a pharmacist's ability to disclose whether the cost-sharing 12obligation exceeds the retail price for a covered prescription 13drug, and the availability of a more affordable alternative 14drug, if one is available in accordance with Section 42 of the 15Pharmacy Practice Act. 16    (e) A health insurer or pharmacy benefit manager shall not 17require an insured to make a payment for a prescription drug at 18the point of sale in an amount that exceeds the lesser of: 19        (1) the applicable cost-sharing amount; or20        (2) the retail price of the drug in the absence of 21    prescription drug coverage. 22    (f) Unless required by law, a contract between a pharmacy 23benefit manager or third-party payer and a 340B entity or 340B 24pharmacy shall not contain any provision that: 25        (1) distinguishes between drugs purchased through the 26    340B drug discount program and other drugs when   HB3794- 17 -LRB104 10437 BAB 20512 b1    determining reimbursement or reimbursement methodologies, 2    or contains otherwise less favorable payment terms or 3    reimbursement methodologies for 340B entities or 340B 4    pharmacies when compared to similarly situated non-340B 5    entities; 6        (2) imposes any fee, chargeback, or rate adjustment 7    that is not similarly imposed on similarly situated 8    pharmacies that are not 340B entities or 340B pharmacies; 9        (3) imposes any fee, chargeback, or rate adjustment 10    that exceeds the fee, chargeback, or rate adjustment that 11    is not similarly imposed on similarly situated pharmacies 12    that are not 340B entities or 340B pharmacies; 13        (4) prevents or interferes with an individual's choice 14    to receive a covered prescription drug from a 340B entity 15    or 340B pharmacy through any legally permissible means, 16    except that nothing in this paragraph shall prohibit the 17    establishment of differing copayments or other 18    cost-sharing amounts within the benefit plan for covered 19    persons who acquire covered prescription drugs from a 20    nonpreferred or nonparticipating provider; 21        (5) excludes a 340B entity or 340B pharmacy from a 22    pharmacy network on any basis that includes consideration 23    of whether the 340B entity or 340B pharmacy participates 24    in the 340B drug discount program; 25        (6) prevents a 340B entity or 340B pharmacy from using 26    a drug purchased under the 340B drug discount program; or   HB3794- 18 -LRB104 10437 BAB 20512 b1        (7) any other provision that discriminates against a 2    340B entity or 340B pharmacy by treating the 340B entity 3    or 340B pharmacy differently than non-340B entities or 4    non-340B pharmacies for any reason relating to the 5    entity's participation in the 340B drug discount program.6     (g-5) A covered individual's defined cost sharing for 7each prescription drug shall be calculated at the point of 8sale based on a price that is reduced by an amount equal to at 9least 80% of all rebates received or to be received in 10connection with the dispensing or administration of the 11prescription drug.12    In complying with this Section, a health insurer or its 13agents shall not publish or otherwise reveal information 14regarding the actual amount of rebates a health insurer 15receives on a product or therapeutic class of products, 16manufacturer-specific basis, or pharmacy-specific basis. The 17information described in this subsection is: (i) considered 18protected as a trade secret; (ii) considered proprietary and 19confidential; (iii) not subject to disclosure under the 20federal Freedom of Information Act or the Freedom of 21Information Act; and (iv) not to be disclosed directly, 22indirectly, or in a manner that would either allow for the 23identification of an individual product, therapeutic class of 24products, or manufacturer or have the potential to compromise 25the financial, competitive, or proprietary nature of the 26information. A health insurer shall impose the confidentiality   HB3794- 19 -LRB104 10437 BAB 20512 b1protections of this subsection on any vendor or other third 2party that performs health care or administrative services on 3behalf of the health insurer that may receive or have access to 4rebate information. 5    Nothing in this subsection precludes a pharmacy benefit 6manager or insurer from reducing an insured's cost sharing by 7an amount greater than that required under this subsection.8    As used in this subsection, "pharmacy benefit manager" and 9"third-party payer" do not include pharmacy benefit managers 10and third-party payers acting on behalf of a Medicaid program. 11    (g) A violation of this Section by a pharmacy benefit 12manager constitutes an unfair or deceptive act or practice in 13the business of insurance under Section 424. 14    (h) A provision that violates subsection (f) in a contract 15between a pharmacy benefit manager or a third-party payer and 16a 340B entity that is entered into, amended, or renewed after 17July 1, 2022 shall be void and unenforceable. 18    (i)(1) A pharmacy benefit manager may not retaliate 19against a pharmacist or pharmacy for disclosing information in 20a court, in an administrative hearing, before a legislative 21commission or committee, or in any other proceeding, if the 22pharmacist or pharmacy has reasonable cause to believe that 23the disclosed information is evidence of a violation of a 24State or federal law, rule, or regulation.25    (2) A pharmacy benefit manager may not retaliate against a 26pharmacist or pharmacy for disclosing information to a   HB3794- 20 -LRB104 10437 BAB 20512 b1government or law enforcement agency, if the pharmacist or 2pharmacy has reasonable cause to believe that the disclosed 3information is evidence of a violation of a State or federal 4law, rule, or regulation.5    (3) A pharmacist or pharmacy shall make commercially 6reasonable efforts to limit the disclosure of confidential and 7proprietary information.8    (4) Retaliatory actions against a pharmacy or pharmacist 9include cancellation of, restriction of, or refusal to renew 10or offer a contract to a pharmacy solely because the pharmacy 11or pharmacist has:12        (A) made disclosures of information that the 13    pharmacist or pharmacy has reasonable cause to believe is 14    evidence of a violation of a State or federal law, rule, or 15    regulation;16        (B) filed complaints with the plan or pharmacy benefit 17    manager; or18        (C) filed complaints against the plan or pharmacy 19    benefit manager with the Department.20    (j) This Section applies to contracts entered into or 21renewed on or after July 1, 2022, except that subsection (g-5) 22applies to contracts entered into or renewed on or after 23January 1, 2026. 24    (k) This Section applies to any group or individual policy 25of accident and health insurance or managed care plan that 26provides coverage for prescription drugs and that is amended,   HB3794- 21 -LRB104 10437 BAB 20512 b1delivered, issued, or renewed on or after July 1, 2020. 2(Source: P.A. 102-778, eff. 7-1-22; 103-154, eff. 6-30-23; 3103-453, eff. 8-4-23.) 4    Section 15. The Pharmacy Practice Act is amended by 5changing Section 19.5 as follows: 6    (225 ILCS 85/19.5)7    (Section scheduled to be repealed on January 1, 2028)8    Sec. 19.5. Biological products.9    (a) For the purposes of this Section:10    "Biological product" has the meaning given to that term in 1142 U.S.C. 262.12    "Interchangeable biological product" means a biological 13product that the United States Food and Drug Administration:14        (1) has (A) licensed and (B) determined it to meet the 15    standards for interchangeability pursuant to 42 U.S.C. 16    262(k)(4); or 17        (2) has determined is therapeutically equivalent as 18    set forth in the latest edition of or supplement to the 19    United States Food and Drug Administration's Approved Drug 20    Products with Therapeutic Equivalence Evaluations (Orange 21    Book).22    (b) A pharmacist may substitute a an interchangeable 23biological product for a prescribed biological product only if 24all of the following conditions in this subsection (b) are   HB3794- 22 -LRB104 10437 BAB 20512 b1met:2        (1) the product being considered for substitution is 3    either the reference product or a product approved by the 4    United States Food and Drug Administration as a biosimilar 5    of the prescribed biological product; the substituted 6    product has been determined by the United States Food and 7    Drug Administration to be interchangeable, as defined in 8    subsection (a) of this Section, with the prescribed 9    biological product;10        (2) the prescribing physician does not designate 11    orally, in writing, or electronically that substitution is 12    prohibited in a manner consistent with Section 25 of this 13    Act; and14        (3) the pharmacy informs the patient of the 15    substitution.16    (c) Within 5 business days following the dispensing of a 17biological product, the dispensing pharmacist or the 18pharmacist's designee shall make an entry of the specific 19product provided to the patient, including the name of the 20product and the manufacturer. The communication shall be 21conveyed by making an entry that can be electronically 22accessed by the prescriber through:23        (1) an interoperable electronic medical records 24    system;25        (2) an electronic prescribing technology;26        (3) a pharmacy benefit management system; or   HB3794- 23 -LRB104 10437 BAB 20512 b1        (4) a pharmacy record. 2    Entry into an electronic records system as described in 3this subsection (c) is presumed to provide notice in 4accordance with this subsection (c). Otherwise, the pharmacist 5shall communicate the biological product dispensed to the 6prescriber using facsimile, telephone, electronic 7transmission, or other prevailing means, except that 8communication shall not be required if where: (A) there is no 9United States Food and Drug Administration-approved 10interchangeable biological product for the product prescribed; 11or (B) a refill prescription is not changed from the product 12dispensed on the prior filling of the prescription. 13    (d) The pharmacy shall retain a record of the biological 14product dispensed for a period of 5 years.15    (e) (Blank). The Department shall maintain a link on its 16Internet website to the current list of all biological 17products determined by the United States Food and Drug 18Administration to be interchangeable with a specific 19biological product.20    (f) The Department may adopt rules for compliance with 21this Section.22(Source: P.A. 99-200, eff. 1-1-16.)